{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"description":"The clinical benefit response, defined as the proportion of subjects achieving a best overall response of MR or better per investigator assessment per IMWG at or prior to initiation of subsequent anticancer therapy.","groups":[{"description":"Ibrutinib PO+ Pomalidomide PO+ Dexamethasone PO\n\nIbrutinib (560mg)\n\nPomalidomide (4mg)\n\nDexamethasone (40mg)","id":"OG000","title":"Phase 1: Dose Finding (560mg)"},{"description":"Ibrutinib PO+ Pomalidomide PO+ Dexamethasone PO\n\nIbrutinib (840mg)\n\nPomalidomide (4mg)\n\nDexamethasone (40mg)","id":"OG001","title":"Phase 1: Dose Finding (840mg)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"14 Months","title":"Clinical Benefit Response (CBR)","type":"SECONDARY","unitOfMeasure":"Participants"}